Updated:
Stallergenes Greer Ltd
Stallergenes Greer Ltd is a London-based immunotherapy company treating allergic respiratory diseases with products like Acarizax® and Oralair® worldwide.
Stallergenes Greer Ltd
Stallergenes Greer Ltd was formed in 2016 through the merger of France-based Stallergenes and US-based Greer Laboratories, uniting two allergy immunotherapy pioneers under a London holding company. The firm traces its roots to 1929 with Greer's founding in North Carolina and Stallergenes' origins in 1962 near Paris. Michèle Ollivier has served as CEO since 2018, overseeing a strategy centered on sublingual immunotherapy tablets and allergy diagnostic products. The company's core business is developing and commercializing allergen immunotherapy treatments for respiratory allergies such as hay fever and allergic asthma. Key products include Oralair®, a grass pollen sublingual tablet, and Acarizax®/Odactra® for house dust mite allergies, which are marketed in over 30 countries. Stallergenes Greer operates manufacturing facilities in Antony, France, and Lenoir, North Carolina, producing standardized allergen extracts. The firm holds a significant share of the global allergy immunotherapy market, competing primarily with ALK-Abelló and Merck KGaA. Stallergenes Greer reported €435 million in revenue for 2023 (per the firm's annual report). The company employs over 2,600 staff across its three main sites and maintains a presence in Europe, North America, and Asia-Pacific. In July 2023, the firm announced regulatory approval for Acarizax® in Japan for allergic rhinitis, marking expansion into a major new market (per Stallergenes Greer press release, July 2023). Stallergenes Greer is majority-owned by Cinven, a private equity firm that acquired Stallergenes in 2013, with a public float on Euronext Paris. A structural differentiator is Stallergenes Greer's integrated model spanning research, manufacturing, and commercialization of both tablet and injectable immunotherapy. The firm operates under a public company governance with the transparency of Euronext listing while benefiting from the long-term backing of a private equity parent. Its focus exclusively on allergy — a single therapeutic category — contrasts with diversified pharma groups and allows deep specialization in product standardization and regulatory pathways.
General information
Firm type
other
Year founded
1929
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Additional offices
Antony, France · Lenoir, North Carolina, United States
Principals
Michèle Ollivier
Chief Executive Officer
Alain Rolland
Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Stallergenes Greer?
As a publicly traded company on Euronext Paris with a controlling shareholder (Cinven), investment decisions are made by the board of directors and executive committee. CEO Michèle Ollivier oversees strategy and operations, with capital allocation decisions subject to board approval under the chairmanship of Jean-Marie Mognetti, a Cinven partner (per public filings).
How does Stallergenes Greer source proprietary deal flow?
Stallergenes Greer primarily grows through internal R&D and regulatory expansion rather than acquisitions. The firm's pipeline emerges from its own research facilities in France and North Carolina. Occasional bolt-on acquisitions, such as the 2016 merger that created the current entity, are sourced through Cinven's network and the firm's own business development team (per company history).
Is Stallergenes Greer structured as a single family office or does it operate more like a venture firm?
Neither. Stallergenes Greer is a publicly operating pharmaceutical company — not a family office, investment firm, or venture capital entity. It trades on Euronext Paris and is majority-controlled by private equity firm Cinven. Its sole business is allergy immunotherapy, making it an operating company with a specialized product portfolio.
Does Stallergenes Greer participate in fund commitments or only direct deals?
Stallergenes Greer does not invest in outside funds or participate as an LP. The firm is an operating pharmaceutical company that funds its own R&D, manufacturing, and commercialization internally. Its capital structure comprises debt and public equity, not a multi-asset investment portfolio.
What investment stages does Stallergenes Greer typically target?
Stallergenes Greer does not make investments as an allocator. Its corporate development targets late-stage clinical assets or approved products in the allergy space, typically through licensing deals or acquisitions. The 2013 acquisition by Cinven and subsequent merger with Greer represent significant corporate events driven by the controlling shareholder.
Which sectors does Stallergenes Greer explicitly avoid?
The firm is exclusively focused on allergen immunotherapy for respiratory allergies and avoids all other therapeutic areas including autoimmune diseases, oncology, and chronic pain. It does not operate in diagnostics beyond allergy-related skin tests and serum IgE testing used to support immunotherapy prescribing (per product portfolio).
How is Stallergenes Greer related to Cinven?
Cinven, a European private equity firm, is the majority shareholder of Stallergenes Greer, having acquired Stallergenes in 2013 for approximately €700 million. The merger with Greer Laboratories was executed under Cinven's ownership in 2016. Cinven holds a controlling stake and appoints the board chair, but Stallergenes Greer operates as a standalone publicly listed entity with its own management team (per Corporate Filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: